about
Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer typesRituximab: mechanism of actionComplement in monoclonal antibody therapy of cancerPicking the optimal target for antibody-drug conjugatesAACR Cancer Progress Report 2014Essential Components of Cancer EducationGenome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphomaChemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cNK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion.Active choice but not too active: public perspectives on biobank consent models.B-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21Cancer and inflammation: promise for biologic therapy.Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma.Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region.Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma.Synergism between cytosine-guanine oligodeoxynucleotides and monoclonal antibody in the treatment of lymphoma.Elevated soluble IL-2Rα, IL-8, and MIP-1β levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphomaCancer immunotherapy and breaking immune tolerance: new approaches to an old challenge.Biodegradable microparticles loaded with doxorubicin and CpG ODN for in situ immunization against cancer.A genome-wide association study of marginal zone lymphoma shows association to the HLA region.Intestinal helminths regulate lethal acute graft-versus-host disease and preserve the graft-versus-tumor effect in mice.Identification of candidate B-lymphoma genes by cross-species gene expression profiling.Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism.Three steps to breaking immune tolerance to lymphoma: a microparticle approach.Building better monoclonal antibody-based therapeutics.Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular lymphoma in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence Molecular EpidemiEarly treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates.Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemiaWidespread use of complementary and alternative medicine among non-Hodgkin lymphoma survivors.Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphomaElevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma.Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia.Monoclonal antibody mechanisms of action in cancer.CpG oligodeoxynucleotide-based therapy of lymphoid malignancies.A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma.GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is presentPhosphorothyoate oligodeoxynucleotides block nonspecific binding of Cy5 conjugates to monocytes.Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells.CpG oligodeoxynucleotides as immunotherapy in cancer.
P50
Q24170413-8A3D7E2E-F7C0-4426-82BB-44560F23B008Q24607358-199670E2-1C64-40BE-90F7-F67F523268CEQ26860800-611AE0FB-F7ED-4E4A-A10C-BECB56972C4EQ26991588-499EDC16-392F-4B4A-89ED-095ED94D3AF3Q27346723-8521A3E6-73AC-4BF7-83DA-49AEDC59048DQ28088426-8F6FDE8F-09EA-469A-B500-670D5B8528EDQ28248768-B8974032-282E-4DA4-B91B-17EDB2307EC9Q30408922-C85A6308-5A30-4BA2-90BE-1967E112FB87Q30440293-F304429F-568B-4683-95A9-A6B9ACA557D7Q30496008-3695E3A2-B3BE-4358-B162-057872B1AB4CQ30539964-537DC1B2-0E2B-4EBC-A3A1-E360A9F82256Q34048170-638A13FC-22D0-411A-B31D-8BAD6C6B7B95Q34139732-A227544D-4C17-4C8C-95A7-2932168EE2E8Q34193968-91801749-72B5-43AE-AA28-C6D1FBD223E2Q34288685-3801481E-A850-4E70-B092-692659C17236Q34402503-27812BC4-570F-405F-8689-7A17B403A6F2Q34528390-63FB3941-F8D5-46CB-83A4-15202C866C94Q34626318-7C8CB29A-0578-443B-88D8-7605172D8781Q34859794-A1C2708D-8731-46F9-8588-6F200EAC9B62Q34871657-13C6A4C5-79AD-4633-8F58-36F1790F87C0Q34881099-93D04C17-1B86-4341-86F3-5D74E247B013Q34980164-928811D4-99FB-45A1-84AB-0ECD889696ACQ35018604-57761D4B-5A62-47F6-A870-73BEABEE9310Q35230227-447AEC75-16FD-4348-92D4-2393D45B30A5Q35328686-60F52E90-1041-4924-B3A0-5573C2518558Q35817552-C1A1BD68-CD00-4055-8EED-786EBE27F9C8Q35931755-E5E9D0D0-95D0-4E8E-B936-45DC0CA2506DQ36070219-0AA4307C-CD91-4DEA-80BD-A5D04AE1A954Q36222910-79B0C0CF-FA74-4FC7-8E5D-8C37CF9C04F4Q36337973-E5545FC5-544F-434C-A33E-9E76BEBDD961Q36384484-3CAE5EC9-5735-4256-BE21-C9412C945681Q36658320-FC49AB56-C8E9-44DB-B972-691CDAA9EC2EQ36675182-79633987-5A34-415D-A263-14D034E9C475Q36961106-879F54FC-822A-49A1-8851-0F4554824682Q37376980-CA84FA28-B1EA-4559-92C4-5B19743DF2C3Q38259725-CBF0BAEF-9E0A-40FD-A8A4-4DC1E7B9D68AQ38315579-B917A9C1-B366-482B-A6AE-BBF13A726447Q38329172-DD5B5288-02B7-4073-B061-89722CBDCBD3Q38333437-3717BEA7-600C-447A-A869-5CA5D8129B77Q38570179-C5D056FA-BF85-4F8D-BDC6-3421E13C4050
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
George J Weiner
@ast
George J Weiner
@en
George J Weiner
@es
George J Weiner
@nl
type
label
George J Weiner
@ast
George J Weiner
@en
George J Weiner
@es
George J Weiner
@nl
altLabel
Weiner GJ
@en
george weiner
@en
prefLabel
George J Weiner
@ast
George J Weiner
@en
George J Weiner
@es
George J Weiner
@nl
P106
P1153
7004589365
P31
P496
0000-0003-3427-0562